Literature DB >> 1511036

A sensitive and reproducible HPLC assay for doxorubicin and pirarubicin.

J M Jacquet1, M Galtier, F Bressolle, J Jourdan.   

Abstract

A high-performance liquid chromatographic method with spectrofluorometric detection has been developed for the analysis of doxorubicin (DOX), pirarubicin (PIRA) and their metabolite, doxorubicinol, in plasma. The detection was performed at 480 nm for excitation, and 590 nm for emission. The proposed technique is selective, reliable, and sensitive. The limit of quantification was 2 ng ml-1 for DOX and 5 ng ml-1 for PIRA. The reproducibility of the analytical method through statistical coefficients is approximately 5%. The accuracy of the method is good; the relative error is less than 5%.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511036     DOI: 10.1016/0731-7085(92)80050-w

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

Review 1.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.

Authors:  F Bressolle; J M Jacquet; M Galtier; J Jourdan; D Donadio; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.

Authors:  D Marchiset-Leca; F R Leca; A Galeani; A Noble; J Catalin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.